Drug side effects
lemborexant Side Effects
The reactions most often reported to the FDA for lemborexant (also sold as Dayvigo), with demographics, serious outcomes, and reporting trends.
Data updated 2026-05-15
- 2,425
- FAERS reports
Data from the FDA Adverse Event Reporting System (FAERS), 2015 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.
The most commonly reported side effects of lemborexant come from 2,425 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.
This page analyzes 2,425 reports to the FDA Adverse Event Reporting System (FAERS) for lemborexant (Dayvigo): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.
Total Reports
2,425
Reports Mentioning Death
267
11.0% of reports — not proof the medicine caused the death
Hospitalizations
1,064
43.9% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 267 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 32 |
| PNEUMONIA | 22 |
| INTERSTITIAL LUNG DISEASE | 20 |
| DECREASED APPETITE | 17 |
| PNEUMONIA ASPIRATION | 17 |
| CYTOKINE RELEASE SYNDROME | 15 |
| PYREXIA | 15 |
| COMPLETED SUICIDE | 12 |
| FALL | 12 |
| HEPATIC FUNCTION ABNORMAL | 11 |
| NAUSEA | 11 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 10 |
| PLEURAL EFFUSION | 10 |
| CARDIAC FAILURE | 9 |
| MALIGNANT NEOPLASM PROGRESSION | 9 |
| SEPSIS | 9 |
| CEREBRAL INFARCTION | 8 |
| DIARRHOEA | 8 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 8 |
Reactions in Hospitalization Reports
Top reactions in 1,064 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| SUICIDE ATTEMPT | 120 |
| CONDITION AGGRAVATED | 105 |
| SUICIDAL IDEATION | 101 |
| ADVERSE DRUG REACTION | 58 |
| FALL | 53 |
| PYREXIA | 49 |
| ALTERED STATE OF CONSCIOUSNESS | 47 |
| PNEUMONIA | 44 |
| DECREASED APPETITE | 41 |
| INTENTIONAL OVERDOSE | 41 |
| INTERSTITIAL LUNG DISEASE | 41 |
| SOMNOLENCE | 39 |
| MALAISE | 36 |
| OVERDOSE | 36 |
| DIZZINESS | 34 |
| HEPATIC FUNCTION ABNORMAL | 33 |
| DIARRHOEA | 32 |
| UNDERDOSE | 31 |
Nearby, Related Medications
What the FAERS Data Reveals About lemborexant Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 2,425 voluntary reports linked to lemborexant and its brand equivalents (Dayvigo), spanning 2015 through 2025. Of those, 267 (11.0%) listed death as an outcome and 1,064 (43.9%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 56% were female and 44% male; age distribution skews toward 65-74, with 474 reports in that bracket. The single most reported reaction is suicide attempt with 133 submissions, followed by somnolence and condition aggravated.
How to read these numbers
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.
Drugs With a Similar FAERS Report Volume
Other medications with a total FDA adverse-event report count closest to lemborexant's 2,425.
Read our methodology - how this data is sourced, computed, and verified.